Comparative Pharmacology
Head-to-head clinical analysis: AUROVELA 1 20 versus TRI LO MILI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUROVELA 1 20 versus TRI LO MILI.
AUROVELA 1/20 vs TRI-LO-MILI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive; suppresses gonadotropin (FSH, LH) release, inhibiting ovulation, altering cervical mucus, and reducing endometrial receptivity.
Combination oral contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on the hypothalamic-pituitary axis; norgestimate binds to progesterone receptors, inhibiting ovulation and altering cervical mucus and endometrial receptivity.
One tablet orally once daily at the same time each day for 21 days, followed by 7 placebo tablets. Each tablet contains ethinyl estradiol 0.02 mg and norethindrone acetate 1 mg.
One tablet orally once daily for 21 days, followed by 7 days of placebo.
None Documented
None Documented
Norethindrone: ~8–11 hours (terminal); ethinyl estradiol: ~13–19 hours (terminal). Steady-state achieved within 5–7 days.
Terminal elimination half-life: 20-24 hours; allows once-daily dosing for contraceptive efficacy.
Renal (30–40% as metabolites, <5% unchanged); biliary/fecal (40–60% as metabolites).
Renal: approximately 50% as metabolites; biliary/fecal: approximately 40% as metabolites; 10% unchanged in urine.
Category C
Category C
Oral Contraceptive
Oral Contraceptive